Comparison
Semaglutide vs TB-500
Side-by-side of Semaglutide and TB-500. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
TB-500
TB-500 peptide, a 17-aa thymosin beta-4 fragment. Preclinical tendon and wound healing via actin sequestration. Typical dosage 2 to 5 mg weekly. No human RCTs.
Effects at a glance
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
TB-500
- •17-amino-acid fragment of endogenous Thymosin Beta-4, an actin-sequestering peptide
- •Preclinical models show accelerated tendon, ligament, and dermal wound healing
- •Equine veterinary use for soft-tissue injury is the most documented real-world application
- •Anecdotal human protocols use 2 to 5 mg twice weekly subcutaneously for 4 to 6 weeks
- •WADA banned under S2 (peptide hormones, growth factors) since 2018
- •No completed phase II or III human RCTs as of 2026; long-term safety unestablished
Side-by-side
| Attribute | Semaglutide | TB-500 |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Ozempic, Wegovy, Rybelsus | Thymosin Beta-4 fragment, TB4-Frag, Thymosin Beta 4 |
| Half-life (hr) ↗ | 168 | 2 |
| Typical dose (mg) ↗ | 2.4 | 2.5 |
| Dosing frequency | weekly (SC); daily (oral Rybelsus) | 2x weekly (anecdotal protocols) |
| Routes | subcutaneous, oral | subcutaneous, intramuscular |
| Onset (hr) | 24 | - |
| Peak (hr) | 72 | - |
| Molecular weight | 4113.58 | 4963.4 |
| Molecular formula | - | C212H350N56O78S |
| Mechanism | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. | Sequesters G-actin monomers, modulates cell migration and angiogenesis, and upregulates VEGF and myosin transcription. Promotes endothelial differentiation and stem-cell migration to injury sites in preclinical models. |
| Legal status | Prescription only (FDA-approved, EMA-approved) | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Not recommended; discontinue 2 months before planned pregnancy | Insufficient data |
| CAS | 910463-68-2 | 885340-08-9 |
| PubChem CID | 56843331 | 62707662 |
| Wikidata | Q27089394 | Q7799921 |
Safety profile
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
TB-500
Common side effects
- injection-site irritation
- fatigue (anecdotal)
- lethargy in early dosing (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established human safety profile
Interactions
- BPC-157: Frequently co-administered in anecdotal healing protocols; no controlled interaction data(minor)
Which Should You Take?
Semaglutide comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. TB-500 is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
- → If your priority is post-training recovery, pick TB-500.
- → If your priority is tendon repair, pick TB-500.
Edge case: If you cannot self-administer injections, Semaglutide is the only oral option in this pair.
Default choice: Semaglutide. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for TB-500 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Semaglutide and TB-500?
Semaglutide and TB-500 differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Semaglutide or TB-500?
Semaglutide half-life is 168 hours; TB-500 half-life is 2 hours.
Can you stack Semaglutide with TB-500?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper